Korea S.E.
06:00:00 2024-05-09 pm EDT
5-day change
1st Jan Change
3,775
KRW
-0.40%
-0.53%
-8.15%
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till July 13, 2020.
On July 12, 2019, the company announced that it has extended its plan duration till July 13, 2020.
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 14, 2023.
23-10-16
CI
Hyundai Pharmaceutical Co., Ltd.(KOSE:A004310) dropped from S&P Global BMI Index
23-09-18
CI
Hyundai Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.
23-07-14
CI
Hyundai Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
23-07-13
CI
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 23, 2022.
23-06-22
CI
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 23, 2022.
23-06-22
CI
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 23, 2022.
23-06-22
CI
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 23, 2022.
23-06-22
CI
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 23, 2022.
23-06-22
CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 23, 2022, has expired with 968,118 shares, representing 3.50% for KRW 4,388.11 million.
23-06-21
CI
Hyundai Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares.
22-06-23
CI
Hyundai Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
22-06-22
CI
Market Chatter: Hyundai Pharmaceutical Seeks Regulatory Approval to Market Abortion Pill in South Korea
21-07-07
MT
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 14, 2008, has expired.
21-04-07
CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback announced on April 22, 2010, has expired.
21-04-07
CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 28, 2019, has expired.
21-04-07
CI
Hyundai Pharmaceutical Co., Ltd.(KOSE:A004310) added to S&P Global BMI Index
20-09-21
CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till June 25, 2021.
20-06-25
CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till April 16, 2021.
20-04-13
CI
Tranche Update on Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 28, 2019.
19-09-26
CI
Hyundai Pharmaceutical Co., Ltd.(KOSE:A004310) dropped from S&P Global BMI Index
19-09-23
CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till July 13, 2020.
19-07-11
CI
Hyundai Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.
19-06-28
CI
Hyundai Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
19-06-27
CI
Hyundai Pharmaceutical Co., Ltd.'s Equity Buyback Plan Extended till April 17, 2020.
19-04-17
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
HYUNDAI PHARMACEUTICAL CO.,LTD is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals and beverages. The Company mainly provides two categories of products: pharmaceuticals, including ophthalmological tablets, clopidogrel bisulfate, mirtazapine tablets and others, which are applied in the treatment of depressive disorder, hypertension, hemostatics and others, as well as healthcare food products, including vitamin products, calcium supplements and others. It also provides dietary various beverages and medical equipment. The Company mainly distributes its products within domestic market. In addition, the Company also involves in the leasing business.
More about the company
1st Jan change
Capi.
-8.15% 76.83M +19.62% 42.97B +24.52% 22.49B +20.29% 14.93B +7.48% 13.14B +42.51% 11.67B -8.84% 6.86B -0.05% 6.79B -8.87% 5.73B +13.13% 5.54B
Generic Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
HYUNDAI PHARMACEUTICAL CO., LTD. 